Investment Rating - The industry rating is maintained at "Overweight" [6] Core Insights - The Chinese medicine sector experienced a significant decline, with the Chinese medicine index dropping by 2.03% last week, while other pharmaceutical sub-sectors also faced declines, except for medical services which saw a 1.67% increase [1][19] - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.17X, down by 0.55X week-on-week, while the price-to-book (PB) ratio is 2.29X, down by 0.04X week-on-week [2] - The demand for flu-related and tonic herbs has increased, leading to a rise in the price index of Chinese medicinal materials, which is expected to continue to rise slightly in the future [3] - The national medical insurance work conference highlighted the restructuring of prices and market patterns as a major direction for the Chinese medicine industry in 2026, emphasizing the importance of collective procurement and support for innovation in the industry [4][9] Summary by Sections Market Performance - The Chinese medicine index closed at 6372.09 points, down 2.03% last week, with only the medical services sector recording positive returns [1][19] Valuation - The current PE ratio for the Chinese medicine sector is 27.17X, with a year-high of 30.26X and a year-low of 24.72X, placing it at the 28.41% percentile since 2013 [2] Supply Chain Insights - The price index for Chinese medicinal materials rose to 225.57 points, a 0.4% increase from the previous week, driven by increased demand due to the flu outbreak and winter tonic herbs [3] Policy and Market Trends - The 2026 direction for the Chinese medicine industry includes continued promotion of collective procurement and support for innovation, with an emphasis on price governance and market restructuring [4][10] - The focus on long-term care insurance is expected to increase demand for Chinese medicine products, particularly in the context of an aging population [9] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, with specific recommendations for companies with strong R&D capabilities and unique products [10][11]

Core Insights - The Chinese health industry is entering a significant growth phase, driven by an aging population and increasing acceptance of traditional Chinese medicine [2] - Shouxiangu aims to become a leading brand in organic Chinese medicine and global Lingzhi products, focusing on product quality and consumer trust [3] Company Strategy - Shouxiangu's main products include third-generation wall-breaking Lingzhi spore powder and Dendrobium candidum series, with Lingzhi spore powder accounting for approximately 72% of sales in the first half of 2025 [3] - The company is expanding its market presence outside Zhejiang province, where current sales account for less than 10% [3][4] - Shouxiangu plans to adopt a dual approach for expansion, including learning from successful distributors and forming strategic partnerships with well-known pharmaceutical distribution companies [4] Digital Transformation - The company is leveraging AI technology to enhance production efficiency and product quality, while also utilizing digital marketing to improve customer engagement and conversion rates [4] Industry Challenges - The traditional Chinese medicine sector faces cyclical pressures from high-end consumption contraction and inventory issues, alongside long-term structural challenges [4] - The industry is experiencing a shift in consumer demographics, with younger consumers becoming a significant market segment [4] Marketing and Product Innovation - Shouxiangu is enhancing brand visibility through sponsorships and engaging with new media platforms for broader consumer reach [5] - The company is diversifying its product offerings to appeal to younger consumers, including ready-to-drink products and innovative formats like capsules and oral liquids [5]

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司有考虑跟工程院医药大拿合作开发中药方 吗？ 寿仙谷（603896.SH）12月12日在投资者互动平台表示，公司与李玉、孙宝国、朱蓓薇等多位中国工程 院院士在食药用菌育种、栽培以及药食同源产品开发等领域有深入合作。 ...

Core Viewpoint - The Chinese health industry is entering a significant growth phase, driven by an aging population and increasing acceptance of traditional Chinese medicine, presenting substantial opportunities for companies like Shouxiangu [2] Company Strategy - Shouxiangu aims to become the leading brand in organic traditional medicine and the global leader in Ganoderma lucidum products, focusing on high-quality product offerings such as third-generation broken-wall Ganoderma spore powder and Dendrobium products [3] - The company emphasizes product quality and safety, which has garnered consumer trust and loyalty [3] - Shouxiangu's core product, Ganoderma spore powder, accounted for approximately 72% of sales in the first half of 2025, with 66.47% of sales occurring in Zhejiang Province [3] Market Expansion - The company is actively working to expand its market presence outside Zhejiang Province, where current sales are less than 10% [4] - Shouxiangu plans to adopt a dual approach for expansion: learning from successful models like those of Pianzihuang and Guizhou Moutai for rapid channel development and forming strategic partnerships with well-known pharmaceutical distribution companies [4] Digital Transformation - Digital empowerment is a key focus, with the company utilizing AI technology to enhance production efficiency and product quality, as well as employing digital marketing strategies to improve customer engagement and conversion rates [4] Industry Challenges - The traditional Chinese medicine sector faces pressures from high-end consumer contraction and inventory reduction cycles, necessitating a shift towards high-quality development [5] - Structural challenges include the need for traditional companies to innovate or risk marginalization, as well as changing consumer demographics with younger consumers becoming a significant market segment [5] Product Innovation - In response to the health trends among younger consumers, Shouxiangu is developing new products such as fermented drinks, snacks, and health teas, catering to various consumption scenarios [6] - The company is also innovating in product forms, offering tablets, capsules, and liquid forms to meet consumer demands for convenience [6]

专题：2025中国企业竞争力年会 专题：2025中国企业竞争力年会 "2025中国企业竞争力年会"于12月9日至10日在北京举行，浙江寿仙谷医药股份有限公司董事会秘书刘 国芳在演讲中介绍，她是寿仙谷灵芝孢子粉的忠实粉丝，是从39岁开始服用灵芝孢子粉的，服用11年 了，今年50岁了，给她三个感受： 第一个是睡眠特别好，一沾枕头就睡； 第二个是11年没有吃过一粒感冒药，包括阳了也没有吃过药，就是每一天精力旺盛，白天精神好，晚上 睡得好； 第三个是她11年也没跨入过美容院，但皮肤老化的速度相对来说还是比较慢的。 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 责任编辑：李思阳 "2025中国企业竞争力年会"于12月9日至10日在北京举行，浙江寿仙谷医药股份有限公司董事会秘书刘 国芳在演讲中介绍，她是寿仙谷灵芝孢子粉的忠实粉丝，是从39岁开始服用灵芝孢子粉的，服用11年 了，今年50岁了，给她三个感受： 第一个是睡眠特别好，一沾枕头就睡； 第二个是11年没有吃过一粒感冒药，包括阳了也没有吃过药，就是每一天精力旺盛，白天精神好，晚上 睡 ...

0:00 浙江寿仙谷医药股份有限公司董事会秘书刘国芳：中国正处于高质量发展的时期，人们对高水平健康的 追求趋势不会变。中国进入了银发经济时代，60岁以上的人口占比达到了30%，人们对中药的功效越来 越接受和认可。所以，未来大健康产业会是一个发展潜力巨大的产业，也会是一个复苏比较快的行业。 ...

证券代码：603896 证券简称：寿仙谷 公告编号：2025-077 债券代码：113660 债券简称：寿22转债 浙江寿仙谷医药股份有限公司 关于举办2025年第二次投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为更好与投资者沟通交流，便于广大投资者全面深入地了解浙江寿仙谷医药股份有限公司（以下简 称"公司"或"寿仙谷"）情况，公司拟举办2025年第二次投资者接待日活动，现将有关事项公告如下： 1、接待时间：2025年12月23日8:50-17:00 2、接待地点：公司基地一寿仙谷有机国药养生园；公司总部一浙江省武义县黄龙三路12号。 3、公司主要参与人员：董事长李明焱、副董事长李振皓、董事兼总经理李振宇、董事兼副总经理林荣 志、董事兼副总经理徐靖、董事黄俊华、副总经理兼董事会秘书刘国芳、财务负责人祝彪、副总经理王 汉波、投资者服务部总监曹秀娟（如遇特殊情况，参会人员会有所调整） 4、活动日程： ■ 注：①投资者可根据自己的行程选择合适的集合地点，公司将统一安排车辆前往基地参观；自驾的投资 者可以将 ...

证券日报网讯 12月9日，寿仙谷在互动平台回答投资者提问时表示，公司已开始布局国际市场，特别是 在中医药文化认同度较高的东南亚地区。 （文章来源：证券日报） ...

浙江寿仙谷医药股份有限公司 关于举办 2025 年第二次投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-077 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 为更好与投资者沟通交流，便于广大投资者全面深入地了解浙江寿仙谷医药 股份有限公司（以下简称"公司"或"寿仙谷"）情况，公司拟举办 2025 年第二 次投资者接待日活动，现将有关事项公告如下： 1、接待时间：2025 年 12 月 23 日 8:50-17:00 2、接待地点：公司基地—寿仙谷有机国药养生园；公司总部—浙江省武义 县黄龙三路 12 号。 3、公司主要参与人员：董事长李明焱、副董事长李振皓、董事兼总经理李 振宇、董事兼副总经理林荣志、董事兼副总经理徐靖、董事黄俊华、副总经理兼 董事会秘书刘国芳、财务负责人祝彪、副总经理王汉波、投资者服务部总监曹秀 娟（如遇特殊情况，参会人员会有所调 ...

公司代码：603896 公司简称：寿仙谷 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 Zhejiang Shouxiangu Pharmaceutical Co., Ltd. （浙江省武义县壶山街道商城路 10 号） 2025 年第二次临时股东会 会议资料 $$=0\pm\pi\pm\pi\pm\pi\pm\pi\pm\pi\pm\pi$$ 浙江寿仙谷医药股份有限公司 2025 年第二次临时股东会会议资料 目 录 | 2025 | 年第二次临时股东会会议议程 2 | | --- | --- | | 2025 | 年第二次临时股东会会议须知 4 | | | 议案一：关于变更公司注册资本、取消监事会暨修订《公司章程》的议案 6 | | | 议案二：关于修订部分公司治理制度的议案 14 | 1 浙江寿仙谷医药股份有限公司 2025 年第二次临时股东会会议资料 浙江寿仙谷医药股份有限公司 2025 年第二次临时股东会会议议程 一、会议召集人：浙江寿仙谷医药股份有限公司董事会 二、会议召开的日期、时间： 现场会议时间：2025 年 12 月 23 日 14:00 网络投票起止时间：自 ...